- Home
- NKTR vs LUNG Comparison
NKTR vs LUNG Comparison
Compare NKTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- LUNG
- Stock Information
- Founded
- NKTR 1990
- LUNG 1995
- Country
- NKTR United States
- LUNG United States
- Employees
- NKTR N/A
- LUNG N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- NKTR Health Care
- LUNG Health Care
- Exchange
- NKTR Nasdaq
- LUNG Nasdaq
- Market Cap
- NKTR 1.2B
- LUNG 65.6M
- IPO Year
- NKTR 1994
- LUNG 2020
- Fundamental
- Price
- NKTR $57.61
- LUNG $1.52
- Analyst Decision
- NKTR Strong Buy
- LUNG Buy
- Analyst Count
- NKTR 6
- LUNG 7
- Target Price
- NKTR $91.67
- LUNG $7.66
- AVG Volume (30 Days)
- NKTR 917.0K
- LUNG 278.6K
- Earning Date
- NKTR 11-06-2025
- LUNG 10-29-2025
- Dividend Yield
- NKTR N/A
- LUNG N/A
- EPS Growth
- NKTR N/A
- LUNG N/A
- EPS
- NKTR N/A
- LUNG N/A
- Revenue
- NKTR $74,934,000.00
- LUNG $90,549,000.00
- Revenue This Year
- NKTR N/A
- LUNG $10.30
- Revenue Next Year
- NKTR N/A
- LUNG $14.72
- P/E Ratio
- NKTR N/A
- LUNG N/A
- Revenue Growth
- NKTR N/A
- LUNG 18.24
- 52 Week Low
- NKTR $6.48
- LUNG $1.47
- 52 Week High
- NKTR $63.92
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- NKTR 60.53
- LUNG 40.08
- Support Level
- NKTR $53.73
- LUNG $1.55
- Resistance Level
- NKTR $58.40
- LUNG $1.64
- Average True Range (ATR)
- NKTR 3.78
- LUNG 0.10
- MACD
- NKTR -1.17
- LUNG -0.01
- Stochastic Oscillator
- NKTR 51.23
- LUNG 0.00
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.